ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 226

Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both

Daisy Bang1, Jinfeng Xu2, Robert T. Keenan3, Virginia Pike1, Aaron Lehmann1, Craig T. Tenner4, Daria Crittenden1, Michael H. Pillinger1 and Svetlana Krasnokutsky1, 1Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, 2Biostatistics, New York University School of Medicine, New York, NY, 3Rheumatology, Duke University, Durham, NC, 4Medicine, NYU School of Medicine, New York, NY

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, gout, osteoarthritis and risk

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Metabolic and Crystal Arthropathies Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Osteoarthritis
(OA) and gout are each associated with increased cardiovascular disease (CVD),
but their relative impacts on CV risk are not known. We compared rates of CVD
among patients with OA (OA-only), gout (gout-only), or both (gout+OA).

Methods:  We used ICD-9 codes to identify male
patients from within our VA health care system with OA-only, gout-only, or gout+OA, and an active medical record between August 2007
and August 2008. For each group, we collected baseline demographics and CVD
risk factors. The primary outcome was a composite index (CV4) consisting of any
diagnosis of myocardial infarction (MI), angina, coronary bypass surgery (CABG),
and/or coronary artery disease (CAD). Secondary outcomes included individual
diagnoses within the CV4, congestive heart failure (CHF) and death. Logistic
regression was used to compare the associations of OA-only, gout-only, and gout+OA with CV outcomes, adjusting for traditional CV risk
factors: age, race, hypertension (HTN), diabetes mellitus, hyperlipidemia (HLD),
chronic kidney disease (CKD), and smoking.  

Results:  1280 gout subjects met inclusion criteria (983
gout-only, 297 gout+OA), along with 1231 OA-only
subjects. Gout subjects, with or without OA, had more CVD risk factors at
baseline, including HTN, HLD and CKD vs. OA-only. In an unadjusted model,
a diagnosis of gout increased the risk for CV4, CAD, angina, CABG, CHF, and death
compared to a diagnosis of OA-only. In a fully adjusted model, gout-only
subjects continued to have increased risk for all outcomes except MI and death
compared to OA-only subjects, while gout+OA subjects
exhibited increased risk for angina and CHF (Table 1). Gout+OA
did not impart additional risk over gout-only for any outcome except CABG.

Conclusion: Our data suggest
that gout is associated with higher risk of CVD compared with OA, that at least
some of this increased risk may be independent of traditional risk factors, and
that OA does not impart additive CVD risk to patients who also have gout.

Table 1. Relative cardiovascular disease outcomes among OA-only, Gout-only and Gout+OA subjects, adjusted for age, race, HTN, HL, DM, CKD, and smoking. Data are odds ratios with 95% confidence intervals and p-values.

Gout-only

vs

OA-only

Gout+OA

vs

OA-only

Gout+OA

vs

Gout-only

CV4

(Primary outcome)

1.271

(1.025,1.574)

p=0.029

1.263

(0.937,1.692)

p=0.121

0.994

(0.739, 1.329)

p=0.967

CAD

1.261

(1.010,1.574)

p=0.040

1.084

(0.796, 1.467)

p=0.604

0.860

(0.634, 1.159)

p=0.325

Angina

4.367

(2.005,10.609)

p<0.001

3.374

(1.233, 9.383)

p=0.017

0.773

(0.337, 1.608)

p=0.513

MI

0.972

(0.487, 1.921)

p=0.936

1.010

(0.356, 2.481)

p=0.984

1.039

(0.371, 2.529)

p=0.937

CABG

3.951

(2.249, 7.176)

p<0.001

1.782

(0.746, 3.961)

p=0.170

0.451

(0.202, 0.905)

p=0.036

CHF

2.379

(1.638, 3.483)

p<0.001

2.209

(1.378, 3.505)

p<0.001

0.929

(0.605, 1.399)

p=0.729

Death

1.30

(0.826, 2.487)

p=0.203

1.870

(0.973, 3.514)

p=0.055

1.308

(0.716, 2.317)

p=0.367


Disclosure: D. Bang, None; J. Xu, None; R. T. Keenan, AstraZeneca, 5; V. Pike, None; A. Lehmann, None; C. T. Tenner, None; D. Crittenden, Amgen Inc, 1,Amgen, Inc, 3; M. H. Pillinger, Takeda Inc, 2,AstraZeneca, 5; S. Krasnokutsky, None.

To cite this abstract in AMA style:

Bang D, Xu J, Keenan RT, Pike V, Lehmann A, Tenner CT, Crittenden D, Pillinger MH, Krasnokutsky S. Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-cardiovascular-disease-in-patients-with-gout-osteoarthritis-or-both/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-cardiovascular-disease-in-patients-with-gout-osteoarthritis-or-both/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology